MED Company Profile and Key Details

MED has shown mixed momentum, losing -0.26% over the past week and -9.75% over the past quarter, though year-to-date performance is up 9.18%. Short-term trend indicators are mixed aligned (SMA20 -1.91%, SMA50 -0.41%, SMA200 -11.96%). The stock’s 14-day RSI is 48.88 (neutral), while the ATR of 0.46 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -32.19% below its high and over 11.88% above its low. Average 10-day trading volume of 243.49 thousand shares is in line with the 3-month average of 237.88 thousand, indicating normal recent market interest.

Medifast, Inc. generated EPS of $0.02 over the past year. Five-year average earnings growth is -50.52%. The latest quarter delivered EPS of -$0.21. The next quarter is forecast at -$0.82. Next year's EPS is expected at -$43.21. Analyst sentiment is neutral. Analyst rating data shows there are 0 Strong Buy ratings, 0 Buy ratings, 1 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.50 to $16.50. The high target offers 46.02% upside. The low target suggests 46.02% downside. The mean target is $16.50. This offers 46.02% upside. Medifast, Inc. earnings surprise history is a mixed track record. The quarter that ended November 03, 2025, missed forecasts by 1957.1%. The prior quarter beat by -113.33%. Over the last six quarters, Apple has recorded several small beats. These include 155.56% in August 05, 2024.

Medifast, Inc. last paid a dividend of 0 per share, this equals a trailing yield of roughly 17.57%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $501.46. This means the shares are trading below this model’s fair value.

Medifast, Inc. has 10.99 million shares outstanding. The public float is 9.15 million shares, elevated short interest at 21.41% of float. This equals 2.29 million shares. The short ratio is 11.35 days. Institutional investors hold 82.62% of the float. Insiders own 3.2%. Chard Daniel R holds 149.70 thousand shares, Hoer Michael A. has 8.38 thousand shares and BYRNES KEVIN G has 8.15 thousand shares.

Medifast, Inc. (NYSE:MED) closed at $11.30 USD, losing -$0.06 (-0.54%) from the previous close of $11.36. The stock is currently mid-range between its 52-week high and low $10.10 and $16.66. With a market capitalization of about $124.20 million, Medifast, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.54). Key stats such as the average daily volume over the past year has been around 247.36 thousand shares, volume is running light vs its 52-week average. Headquartered in Baltimore, MD, Medifast, Inc. operates in the Consumer Cyclical sector and the Personal Products & Services industry. Led by CEO Daniel R. Chard, the company employs approximately 504 people and listed since December 30, 1993. Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products in the United States and the Asia-Pacific.

Medifast, Inc. trades at a P/E ratio of 502.79, slightly above the S&P 500 average, with a price-to-sales ratio of 0.29 and a price-to-book ratio of 0.58 suggesting the stock is closer to book value. The P/FCF stands at 193.03, also above market averages.

Medifast, Inc. (NYSE:MED) shares are flat 9.18% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Medifast, Inc. trading at a premium to the broader market with a P/E of 502.79. Analyst sentiment is mixed, with the majority of ratings in Neutral territory and a mean price target of $82.35, suggesting 628.76% upside. Our AI forecast model points to short-term strength (0.62% over two weeks), a medium-term rise (0.71% over three months), and a longer-term loss (-36.55% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Medifast, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.62%, with price expected at $11.37 by February 23, 2026, within a range of $10.83 to $11.93 3-Month Outlook: Projected rise of 0.71%, reaching $11.38 by May 07, 2026, with a range of $10.74 to $11.94. 1-Year Outlook: Projected loss of -36.55%, with price at $7.17 by February 09, 2027, within a range of $4.72 to $7.67.